Area De Salud De Leon Y El Bierzo

The medical center is at the forefront of hematology and oncology research, focusing on innovative treatments for Relapsed or Refractory Multiple Myeloma (RRMM). The center's research aims to enhance the efficacy, safety, and tolerability of novel therapeutic agents, such as ABBV-383, in patients who have undergone multiple prior therapies.

• Relapsed or Refractory Multiple Myeloma (RRMM)
• Monotherapy Efficacy
• Advanced Therapeutic Strategies

By exploring cutting-edge treatments, the center contributes significantly to the development of personalized medicine approaches, offering hope to patients with challenging hematologic malignancies.

Specializing in neuro-oncology, the center conducts pivotal research on glioblastoma, particularly in cases with MGMT-methylation. The focus is on evaluating the toxicity and efficacy of meclofenamate sodium in combination with standard therapies, aiming to improve outcomes for patients with progressive glioblastoma.

• Glioblastoma
• MGMT-Methylation
• Combination Therapy

The center's work in this area is instrumental in advancing therapeutic options and enhancing the quality of life for patients with aggressive brain tumors.

In the realm of cardiovascular medicine, the center is pioneering research on optimizing platelet inhibition in Coronary Acute Syndrome (ACS). Utilizing the VerifyNow® platelet aggregation measurement device, the research explores the benefits of de-escalating from potent antiplatelet agents to clopidogrel, aiming to improve patient outcomes.

• Coronary Acute Syndrome (ACS)
• Platelet Inhibition Optimization
• Antiplatelet Therapy

This research is crucial in refining treatment protocols and enhancing the safety and effectiveness of cardiovascular interventions.